Campbell & CO Investment Adviser LLC Sells 14,681 Shares of DaVita Inc. $DVA

Campbell & CO Investment Adviser LLC lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 59.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,983 shares of the company’s stock after selling 14,681 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in DaVita were worth $1,326,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its holdings in shares of DaVita by 1,951.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 68,408 shares of the company’s stock worth $9,089,000 after acquiring an additional 65,074 shares during the last quarter. Norges Bank purchased a new position in DaVita in the 2nd quarter worth $32,986,000. Edgestream Partners L.P. bought a new stake in DaVita in the second quarter worth $6,375,000. Arrowstreet Capital Limited Partnership lifted its stake in DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after purchasing an additional 150,318 shares during the last quarter. Finally, Sovran Advisors LLC purchased a new stake in DaVita during the second quarter valued at about $472,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 1.0%

Shares of DaVita stock opened at $104.76 on Friday. The business has a 50 day moving average of $116.14 and a 200 day moving average of $127.70. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $179.60. The company has a market cap of $7.40 billion, a PE ratio of 10.79, a P/E/G ratio of 0.64 and a beta of 0.99.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. During the same period in the previous year, the firm posted $2.59 earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of several analyst reports. Cowen reiterated a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. Truist Financial lowered their price objective on DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research report on Monday, January 5th. TD Cowen decreased their target price on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research note on Monday, November 3rd. Finally, Barclays lowered their price target on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a report on Thursday, October 30th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $145.60.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.